Loading company…
Xiaolu Biomedicine develops large-molecule antibody drugs for autoimmune and inflammatory diseases.
Founded in 2025 and based in Suzhou, China, Xiaolu Biomedicine researches antibody drugs for autoimmune and inflammatory diseases. It uses an independently developed antibody technology platform to identify targets and target combinations based on disease mechanisms. In April 2025, it raised angel funding co-led by YuanBio Venture and Together To Miracle Capital, with participation from Oriza Holdings, GL Ventures, Suzhou Capital Group, Shanghai Boquan Equity Investment Management, Beijing Biotechnology Science Park Venture Fund, Beijing Life Science Park Innovation Investment Fund, Hefei Industry Investment Group and other unspecified investors. The funding will support R&D and industrialization.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in